UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 4 | April 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 9 Issue 3
March-2022
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2203666


Registration ID:
500006

Page Number

g514-g525

Share This Article


Jetir RMS

Title

Old Drugs for a Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective

Abstract

The COVID-19 outbreak caused by the SARS-CoV-2 virus in late 2019 and early 2020 comprises a serious pandemic threat worldwide. Given the severity of the disease and the fact that there is no approved cure for this infectious disease, it seems reasonable to search for better candidates' drugs among approved antiviral or even antibacterial drugs for their anti-COVID-19 capability in contrast to the currently approved drugs. The enzyme main protease of SARS-CoV-2 that plays an important role in the virus life cycle seems to be a good target for inhibition by drugs. Accordingly, in the present work by using the molecular docking method, I used the newly released coordinate structure of the protease as a target and 40 approved drugs from anti-viral, anti-parasite anti-malaria groups as ligands for docking experiments. Blind and active site-directed docking experiments were carried out on the optimized and equilibrated structure of protease at pH 7, 37 degrees centigrade of temperature, and 1 atmosphere of pressure. My results indicate that based on binding energy, percentage of binding site occupation, membrane transportability, and the maximum allowed dosage, erythromycin, clarithromycin, amprenavir, darunavir, cefixime, and tetracycline are among the enrolled drugs merit best parameters for clinical evaluation and their therapeutic potential in COVID-19 outbreak.

Key Words

Coronavirus, COVID-19 Outbreak, Docking, Antibiotics, Anti-HIV Drugs, Macrolides

Cite This Article

"Old Drugs for a Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 3, page no.g514-g525, March-2022, Available :http://www.jetir.org/papers/JETIR2203666.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"Old Drugs for a Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 3, page no. ppg514-g525, March-2022, Available at : http://www.jetir.org/papers/JETIR2203666.pdf

Publication Details

Published Paper ID: JETIR2203666
Registration ID: 500006
Published In: Volume 9 | Issue 3 | Year March-2022
DOI (Digital Object Identifier):
Page No: g514-g525
Country: -, -, India .
Area: Engineering
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000200

Print This Page

Current Call For Paper

Jetir RMS